These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11802333)

  • 21. [Rivastigmine: a review of its clinical effectiveness].
    Spiegel R
    Rev Neurol; 2002 Nov 1-15; 35(9):859-69. PubMed ID: 12436385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
    Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS
    Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Domperidone is effective in the prevention of rivastigmine-related gastrointestinal disturbances.
    Scarzella L; Costanza A; Vastola K
    Funct Neurol; 2007; 22(2):101-4. PubMed ID: 17637213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of the therapeutic effects in individual patients with Alzheimer disease].
    Richard E; Lemstra AW; Walstra GJ; van Gool WA
    Ned Tijdschr Geneeskd; 2001 Feb; 145(8):340-5. PubMed ID: 11257811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Ethical aspects of anti-Alzheimer drugs: experiences of caregivers].
    Huizing AR; Berghmans RL; Widdershoven GA; Verhey FR
    Tijdschr Gerontol Geriatr; 2002 Dec; 33(6):246-51. PubMed ID: 12611287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE).
    Gauthier S; Juby A; Dalziel W; Réhel B; Schecter R;
    Curr Med Res Opin; 2010 May; 26(5):1149-60. PubMed ID: 20230208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease].
    Dartigues JF; Goulley F; Bourdeix I; Péré JJ; Barberger-Gateau P
    Rev Neurol (Paris); 2002 Sep; 158(8-9):807-12. PubMed ID: 12386525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term rivastigmine treatment in a routine clinical setting.
    Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
    Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.
    Farlow MR; Lilly ML;
    BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
    Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
    Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
    Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2002 Dec; 56(10):791-6. PubMed ID: 12510954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
    Brassen S; Adler G
    Pharmacopsychiatry; 2003 Nov; 36(6):304-8. PubMed ID: 14663655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.
    Auriacombe S; Pere JJ;
    Curr Med Res Opin; 2003; 19(8):715-7. PubMed ID: 14687442
    [No Abstract]   [Full Text] [Related]  

  • 39. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.
    Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH; Schmand BA
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):545-51. PubMed ID: 17109476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.